Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. März 2025 08:33 ET | Quelle: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
11. März 2025 06:00 ET | Quelle: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
21. März 2017 08:09 ET | Quelle: Innara Health

Innara Health Announces Co-Marketing Agreement with GE Healthcare to Advance Oral Feeding and Neurodevelopment of Premature Infants

Olathe, March 21, 2017 (GLOBE NEWSWIRE) -- Contact Wendy SlateryFOR IMMEDIATE RELEASETelephone 608-213-1449 E-mail wslatery@innarahealth.com Innara Health Announces Co-Marketing Agreement with...